NOVO-B.CO - Novo Nordisk A/S
Novo Nordisk is a Danish pharmaceutical company and the world's leading maker of diabetes treatments, holding a dominant global share of the insulin market. The company has seen extraordinary growth driven by its GLP-1 receptor agonist drugs semaglutide — marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management. The global obesity drug boom has made Novo Nordisk one of Europe's most valuable companies. Its product pipeline also includes treatments for rare blood disorders (haemophilia) and rare endocrine diseases. The Novo Nordisk Foundation, a charitable foundation, controls the company through its ownership structure.
Sector: Healthcare
Why Track NOVO-B.CO with Stocker?
- Real-time price updates and interactive charts
- Consolidate NOVO-B.CO holdings from multiple brokers
- Track your total portfolio value including NOVO-B.CO
- Monitor NOVO-B.CO performance alongside your other investments
- Lifetime portfolio tracking with one time payment
Key Features for NOVO-B.CO Investors
Whether you hold NOVO-B.CO shares through Robinhood, Nordnet, Lunar, or any other broker, Stocker helps you see your complete Novo Nordisk A/S position in one place. No more logging into multiple platforms to check your NOVO-B.CO investments.
Investment Tip: Tracking NOVO-B.CO across multiple brokers? Stocker automatically calculates your total Novo Nordisk A/S holdings, average cost basis, and overall performance metrics in one unified dashboard.